<p>股市的一個偉大之處在於，優秀的股票幾乎可以以任何價格購買，使大多數人都能接觸到。即使只有 100 美元，也可以找到出色的、以增長為導向的公司進行投資。當然，什麼樣的股票被認為是 “最聰明” 的投資選擇因投資者而異，這取決於風險承受能力、目標和投資期限等因素。</p>
<p>一隻交易價格遠低於 100 美元的成長股，能夠滿足許多投資者需求的是 <strong>諾和諾德</strong>（NVO -2.96%）。以下是這家總部位於丹麥的公司為何現在是一個優秀的買入股票的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzY2MTgvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzY2MTgvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>一個絕妙的逆向投資機會</h2>
<p>優質成長股往往備受追捧。這些公司的股票需求通常高於可用股票數量，這就是它們價格上漲的原因。然而，有時這些本來優秀的公司會遇到挑戰，導致拋售，為投資者提供了以折扣價購買其股票的絕妙機會。</p>
<p>在我看來，這就是諾和諾德的現狀。確實，該公司面臨了一些挑戰，並且由於股票價格在過去一年中持續下跌而付出了代價。其財務業績未能達到預期。它在與競爭對手 <strong>禮來</strong> 的競爭中失去了市場份額，並遭遇了一系列意外的臨牀挫折。</p>
<p>然而，諾和諾德的前景依然非常強勁。諾和諾德的聲譽在於它在糖尿病藥物市場上已經佔據了數十年的重要地位。到目前為止，它在糖尿病市場的份額為 32.6%，在 GLP-1 領域的份額為 51.9%。儘管與去年相比，它在這些領域的份額有所下降，但它在這兩個領域仍然是一個主導力量。</p>
<p>諾和諾德在製藥巨頭中繼續保持競爭力的財務業績。該公司上半年的銷售額同比增長了 16%，達到了 1549 億丹麥克朗（242 億美元）。</p>
<p>此外，由於多種因素，糖尿病和肥胖藥物市場正在快速增長。這兩種疾病在最近幾十年中急劇上升，製藥公司現在正在開發高度創新的療法來應對這些問題。諾和諾德仍然處於這場競爭的前沿。即使該公司在市場中的份額較小，但如果市場整體規模大幅增加，這也不是一個重大問題。</p>
<p>諾和諾德能否繼續推出創新藥物，並在大多數競爭對手（不包括禮來）中保持領先？公司的研發管道表明它可以，甚至可能趕上其永恆的競爭對手。考慮一下諾和諾德的潛在三重激動劑（模仿三種腸道激素作用的藥物）UBT251。</p>
<p>在一項為期 12 周的第一階段研究中，UBT251 在最高劑量下平均減重 15.1%。關於早期研究的通常警告適用。然而，UBT251 看起來很有前景，特別是因為目前尚未批准任何單一的三重激動劑用於減重。這只是冰山一角。諾和諾德還有其他幾個令人興奮的候選藥物正在進行各個階段的臨牀開發。而那些已經通過三期研究的藥物，如 CagriSema，應該為這家制藥公司帶來鉅額銷售。</p>
<p>根據一些預測，CagriSema 到 2030 年可能會實現 152 億美元的收入。諾和諾德目前的暢銷藥物 Ozempic 和 Wegovy 預計在本十年末仍將保持全球暢銷藥物的地位。因此，諾和諾德的中期前景似乎樂觀。</p>
<h2>還有更多購買理由</h2>
<p>諾和諾德吸引了以增長為導向的投資者，但對於尋求分紅和撿便宜的投資者來説也是一個不錯的選擇。對於那些尋求收入股票的投資者來説，這家總部位於丹麥的製藥公司是一個不錯的選擇，考慮到其強勁的業績記錄。該公司的前瞻性收益率雖然不算特別，只有 2.9%——儘管這比 <strong>標準普爾 500</strong> 的平均水平 1.3% 要好得多——但諾和諾德在過去十年中持續增加其分紅。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png"/></p>
<p>NVO 分紅（年度）數據來源於 YCharts</p>
<p>最後，諾和諾德的股票交易價格為前瞻性收益的 14 倍，而醫療行業的平均水平為 17.3 倍。儘管最近面臨挑戰，諾和諾德強大的研發管道和產品組合、穩健的收入增長以及在糖尿病和體重管理方面的良好前景使得該股票極具吸引力。該公司的股票目前交易價格約為 59 美元，因此 100 美元可以購買到一股。</p>

諾和諾德公司

<p>諾和諾德公司 (NVO) 被認為是一個值得購買的頂級成長股，價格低於 100 美元，儘管近期面臨挑戰和股價下跌。該公司在糖尿病藥物市場保持強勁地位，市場份額達到 32.6%。其銷售額同比增長 16%，並且正在開發有前景的藥物，包括 UBT251 和 CagriSema。以 14 的前瞻市盈率和 2.9% 的股息收益率，諾和諾德公司為尋求成長和收入的投資者提供了一個有吸引力的投資機會</p>

<p>One of the great things about equity markets is that excellent stocks can be had at almost any price, making them accessible to most people. Even with $100, it's possible to find outstanding, growth-oriented companies to invest in. Of course, what qualifies as &#34;the smartest&#34; stock to buy with any amount of money will differ from one investor to the next, depending on factors such as risk tolerance, goals, and investment horizon.</p>
<div class="lb-trans"><p>股市的一個偉大之處在於，優秀的股票幾乎可以以任何價格購買，使大多數人都能接觸到。即使只有 100 美元，也可以找到出色的、以增長為導向的公司進行投資。當然，什麼樣的股票被認為是 “最聰明” 的投資選擇因投資者而異，這取決於風險承受能力、目標和投資期限等因素。</p>
</div><p>One growth stock trading for well below $100 that can meet many investors' demands is <strong>Novo Nordisk</strong>(NVO -2.96%). Here is why the Denmark-based company is an excellent stock to buy right now.</p>
<div class="lb-trans"><p>一隻交易價格遠低於 100 美元的成長股，能夠滿足許多投資者需求的是 <strong>諾和諾德</strong>（NVO -2.96%）。以下是這家總部位於丹麥的公司為何現在是一個優秀的買入股票的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzY2MTgvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F836618%2Fpatient-self-administering-a-shot.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>A wonderful contrarian opportunity</h2>
<div class="lb-trans"><h2>一個絕妙的逆向投資機會</h2>
</div><p>Quality growth stocks tend to be highly sought after. There is often a higher demand for shares of these companies than are available. That's why their prices rise. Sometimes, though, these otherwise excellent companies encounter challenges that lead to a sell-off, providing investors with a wonderful opportunity to pick up their shares at a discount.</p>
<div class="lb-trans"><p>優質成長股往往備受追捧。這些公司的股票需求通常高於可用股票數量，這就是它們價格上漲的原因。然而，有時這些本來優秀的公司會遇到挑戰，導致拋售，為投資者提供了以折扣價購買其股票的絕妙機會。</p>
</div><p>In my view, that's what we have with Novo Nordisk. True, the company has faced some challenges, and it has paid for them as shares have remained southbound for over a year. Its financial results haven't been as strong as expected. It hit a series of surprising clinical setbacks while losing market share to its rival, <strong>Eli Lilly</strong>.</p>
<div class="lb-trans"><p>在我看來，這就是諾和諾德的現狀。確實，該公司面臨了一些挑戰，並且由於股票價格在過去一年中持續下跌而付出了代價。其財務業績未能達到預期。它在與競爭對手 <strong>禮來</strong> 的競爭中失去了市場份額，並遭遇了一系列意外的臨牀挫折。</p>
</div><p>However, Novo Nordisk's prospects remain very strong. Novo Nordisk's claim to fame is that it has been a major player in the diabetes drug market for decades. That remains the case. As of May, it had a 32.6% share of the diabetes market and a 51.9% share of the GLP-1 space. While its hold in these fields declined compared to last year, it remains a dominant force in both.</p>
<div class="lb-trans"><p>然而，諾和諾德的前景依然非常強勁。諾和諾德的聲譽在於它在糖尿病藥物市場上已經佔據了數十年的重要地位。到目前為止，它在糖尿病市場的份額為 32.6%，在 GLP-1 領域的份額為 51.9%。儘管與去年相比，它在這些領域的份額有所下降，但它在這兩個領域仍然是一個主導力量。</p>
</div><p>Novo Nordisk also continues to post competitive financial results for a pharmaceutical giant. The company's sales for the first half of the year increased by a strong 16% year over year to 154.9 billion Danish kroner ($24.2 billion).</p>
<div class="lb-trans"><p>諾和諾德在製藥巨頭中繼續保持競爭力的財務業績。該公司上半年的銷售額同比增長了 16%，達到了 1549 億丹麥克朗（242 億美元）。</p>
</div><p>Further, the diabetes and obesity drug markets are rising fast due to several factors. Both conditions have skyrocketed in recent decades, and drugmakers are now developing highly innovative therapies to address them. Novo Nordisk is still at the forefront of this race. Even if the company has a smaller slice of the pie, that's not a significant problem if the pie is substantially larger.</p>
<div class="lb-trans"><p>此外，由於多種因素，糖尿病和肥胖藥物市場正在快速增長。這兩種疾病在最近幾十年中急劇上升，製藥公司現在正在開發高度創新的療法來應對這些問題。諾和諾德仍然處於這場競爭的前沿。即使該公司在市場中的份額較小，但如果市場整體規模大幅增加，這也不是一個重大問題。</p>
</div><p>Can Novo Nordisk continue to launch innovative medicines and stay ahead of most of its peers, excluding Eli Lilly? The company's pipeline suggests that it can, and could even catch up with its eternal rival. Consider Novo Nordisk's potential triple agonist (a medicine that mimics the action of three gut hormones), UBT251.</p>
<div class="lb-trans"><p>諾和諾德能否繼續推出創新藥物，並在大多數競爭對手（不包括禮來）中保持領先？公司的研發管道表明它可以，甚至可能趕上其永恆的競爭對手。考慮一下諾和諾德的潛在三重激動劑（模仿三種腸道激素作用的藥物）UBT251。</p>
</div><p>In a 12-week phase 1 study, UBT251 resulted in an average weight loss of 15.1% at the highest dose. The usual caveats regarding early-stage studies apply. Still, UBT251 looks promising, especially since there is no single triple agonist approved for weight loss yet. And that's just the tip of the iceberg. Novo Nordisk has several other exciting candidates through all phases of clinical development. And those that have already passed phase 3 studies, such as CagriSema, should generate massive sales for the drugmaker.</p>
<div class="lb-trans"><p>在一項為期 12 周的第一階段研究中，UBT251 在最高劑量下平均減重 15.1%。關於早期研究的通常警告適用。然而，UBT251 看起來很有前景，特別是因為目前尚未批准任何單一的三重激動劑用於減重。這只是冰山一角。諾和諾德還有其他幾個令人興奮的候選藥物正在進行各個階段的臨牀開發。而那些已經通過三期研究的藥物，如 CagriSema，應該為這家制藥公司帶來鉅額銷售。</p>
</div><p>According to some projections, CagriSema could rack up $15.2 billion in revenue by 2030. Ozempic and Wegovy, Novo Nordisk's current bestsellers, should also remain among the top-selling medicines in the world through the end of the decade. So, Novo Nordisk's medium-term outlook seems promising.</p>
<div class="lb-trans"><p>根據一些預測，CagriSema 到 2030 年可能會實現 152 億美元的收入。諾和諾德目前的暢銷藥物 Ozempic 和 Wegovy 預計在本十年末仍將保持全球暢銷藥物的地位。因此，諾和諾德的中期前景似乎樂觀。</p>
</div><h2>There are more reasons to buy</h2>
<div class="lb-trans"><h2>還有更多購買理由</h2>
</div><p>Novo Nordisk appeals to growth-oriented investors, but it is also a great pick for dividend seekers and bargain hunters. For those seeking income stocks, the Denmark-based drugmaker is a great choice, given its strong track record. The company's forward yield is not exceptional at 2.9% -- although that's much better than the <strong>S&amp;P 500</strong>'s average of 1.3% -- but Novo Nordisk has consistently increased its dividends over the past decade.</p>
<div class="lb-trans"><p>諾和諾德吸引了以增長為導向的投資者，但對於尋求分紅和撿便宜的投資者來説也是一個不錯的選擇。對於那些尋求收入股票的投資者來説，這家總部位於丹麥的製藥公司是一個不錯的選擇，考慮到其強勁的業績記錄。該公司的前瞻性收益率雖然不算特別，只有 2.9%——儘管這比 <strong>標準普爾 500</strong> 的平均水平 1.3% 要好得多——但諾和諾德在過去十年中持續增加其分紅。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png" alt="" original-src="https://media.ycharts.com/charts/139c9b8375922eacc3348b2ceba36a5b.png"/></p>
<p>NVO Dividend (Annual) data by YCharts</p>
<div class="lb-trans"><p>NVO 分紅（年度）數據來源於 YCharts</p>
</div><p>Finally, Novo Nordisk's shares are trading at 14 times forward earnings, whereas the average for the healthcare industry is 17.3. Even with the challenges it has faced recently, Novo Nordisk's strong pipeline and lineup, solid revenue growth, and excellent prospects in diabetes and weight management make the stock highly attractive. The company's shares are changing hands for about $59, so $100 can afford you one of them.</p>
<div class="lb-trans"><p>最後，諾和諾德的股票交易價格為前瞻性收益的 14 倍，而醫療行業的平均水平為 17.3 倍。儘管最近面臨挑戰，諾和諾德強大的研發管道和產品組合、穩健的收入增長以及在糖尿病和體重管理方面的良好前景使得該股票極具吸引力。該公司的股票目前交易價格約為 59 美元，因此 100 美元可以購買到一股。</p>
</div>

目前用 100 美元購買的最明智的成長型股票